These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9853602)

  • 41. Isis and antisense face crucial test without Novartis.
    Dove A
    Nat Biotechnol; 2000 Jan; 18(1):19. PubMed ID: 10625379
    [No Abstract]   [Full Text] [Related]  

  • 42. Gilead is going strong.
    Levenson E
    Fortune; 2009 Mar; 159(6):51-2. PubMed ID: 19351097
    [No Abstract]   [Full Text] [Related]  

  • 43. The genetics of a pharma merger.
    Sanseau P; Chabot-Fletcher M; Browne MJ
    Drug Discov Today; 2009 Apr; 14(7-8):334-6. PubMed ID: 19121408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Industry, clinical trials, and the cost of cancer drugs: an investor's perspective.
    Fiorino T
    J Clin Oncol; 2007 Jul; 25(19):e21-3. PubMed ID: 17602065
    [No Abstract]   [Full Text] [Related]  

  • 45. GlaxoSmithKline, Pfizer to merge HIV drug units in new company.
    AIDS Read; 2009; 19(6):206. PubMed ID: 19642236
    [No Abstract]   [Full Text] [Related]  

  • 46. A billion dollar punt.
    Nat Biotechnol; 2006 Dec; 24(12):1453. PubMed ID: 17160025
    [TBL] [Abstract][Full Text] [Related]  

  • 47. European pharma consolidation generates quality spinoffs.
    Sheridan C
    Nat Biotechnol; 2006 Dec; 24(12):1458-9. PubMed ID: 17160029
    [No Abstract]   [Full Text] [Related]  

  • 48. Roche brings down curtain on Swiss immunology lab.
    Abbott A
    Nature; 2000 Jun; 405(6787):605. PubMed ID: 10864295
    [No Abstract]   [Full Text] [Related]  

  • 49. Payers, consumers benefit as patents expire.
    Manag Care; 2006 Sep; 15(9):72. PubMed ID: 17036942
    [No Abstract]   [Full Text] [Related]  

  • 50. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 51. Sugen falls as casualty of Pfizer-Pharmacia merger.
    Garber K
    Nat Biotechnol; 2003 Jul; 21(7):722-3. PubMed ID: 12833079
    [No Abstract]   [Full Text] [Related]  

  • 52. What does R&D really cost?
    Huff B
    GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
    [No Abstract]   [Full Text] [Related]  

  • 53. [Drug patents distort research].
    Magnusson PA
    Lakartidningen; 2008 Apr 2-8; 105(14):1032. PubMed ID: 18478758
    [No Abstract]   [Full Text] [Related]  

  • 54. Can J & J keep the magic going?
    Taylor A
    Fortune; 2002 May; 145(11):117-20, 122. PubMed ID: 12048959
    [No Abstract]   [Full Text] [Related]  

  • 55. Roche and Igen in shotgun wedding.
    Bouchie A
    Nat Biotechnol; 2003 Sep; 21(9):958. PubMed ID: 12949542
    [No Abstract]   [Full Text] [Related]  

  • 56. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 57. Radical treatments for difficult times.
    Jack A
    BMJ; 2009 Jan; 338():a2955. PubMed ID: 19141500
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharma giants swap research programs.
    Cancer Discov; 2014 Jul; 4(7):OF3. PubMed ID: 25002632
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biotech's new colossus. Move over, Big Pharma. Amgen boasts better growth.
    Stipp D
    Fortune; 2002 Apr; 145(8):144-6, 148, 150. PubMed ID: 11961884
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.